Compare
UL Solutions Inc. vs Medpace Holdings, Inc. vs Charles River Laboratories International, Inc. vs Incyte Corp
| Latest fiscal year | UL Solutions Inc. ULS | Medpace Holdings, Inc. MEDP | Charles River Laboratories International, Inc. CRL | Incyte Corp INCY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-27 | 2025-12-31 |
| Revenue | $3.05B | $2.53B | $4.02B | $5.14B |
| Revenue growth (YoY) | +6.4% | +20.0% | -0.9% | +21.2% |
| Gross margin | 49.5% (computed) | n/a | n/a | 92.8% (computed) |
| Operating margin | 17.1% | 21.1% | 0.6% | 29.5% |
| Net margin | 10.6% | 17.8% | -3.5% | 25.0% |
| Net income | $325.00M | $451.12M | -$142.16M | $1.29B |
| EPS (Diluted) | $1.60 | $15.28 | -$2.91 | $6.41 |
| Operating cash flow | $600.00M | $713.22M | $737.65M | $1.41B |
| Free cash flow | $403.00M | $681.87M | $518.49M | n/a |
| Cash & equivalents | $295.00M | $497.05M | $213.77M | $3.10B |
| Total assets | $2.92B | $1.98B | $7.14B | $6.96B |
| Total liabilities | $1.63B | $1.52B | $3.92B | $1.79B |
| Shareholders' equity | $1.29B | $459.07M | $3.17B | $5.17B |
| Return on year-end equity | 25.1% | 98.3% | -4.5% | 24.9% |
| Shares outstanding | 201.03M | 28.37M | 49.22M | 198.46M |
Revenue, most recent five fiscal years
| Fiscal year | UL Solutions Inc. | Medpace Holdings, Inc. | Charles River Laboratories International, Inc. | Incyte Corp |
|---|---|---|---|---|
| Latest | $3.05B Ended 2025-12-31 | $2.53B Ended 2025-12-31 | $4.02B Ended 2025-12-27 | $5.14B Ended 2025-12-31 |
| 1 year earlier | $2.87B Ended 2024-12-31 | $2.11B Ended 2024-12-31 | $4.05B Ended 2024-12-28 | $4.24B Ended 2024-12-31 |
| 2 years earlier | $2.68B Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $4.13B Ended 2023-12-30 | $3.70B Ended 2023-12-31 |
| 3 years earlier | $2.52B Ended 2022-12-31 | $1.46B Ended 2022-12-31 | $3.98B Ended 2022-12-31 | $3.39B Ended 2022-12-31 |
| 4 years earlier | n/a | $1.14B Ended 2021-12-31 | $3.54B Ended 2021-12-25 | $2.99B Ended 2021-12-31 |